Non–Clear Cell RCC Subtypes Require Individualized Approach to Treatment Selection
December 19th 2023Jaime R. Merchán, MD, spotlights case studies of patients with rare non-ccRCC histologies, discussing their clinical presentation, recent data on immunotherapy and targeted treatment options for the management of these disease subtypes, and patient outcomes on these therapies.
RCC Research May Lead to SOC Improvements and Individualized Treatment Plans
December 15th 2023Marijo Bilusic, MD, PhD, highlights key insights about renal cell carcinoma that were presented at the meeting covering considerations on sequencing TKIs, the need for further research to elucidate novel therapies, and the importance of offering clinical trials to all patients with genitourinary malignancies.
Novel Combination Regimens Are Expanding the Prostate Cancer Treatment Paradigm
December 1st 2023Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.
Dr Stephen D. Nimer Named Researcher of the Year
October 30th 2023BioFlorida, a statewide association for Florida’s life sciences industry, has named Stephen D. Nimer, MD, director of Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, “Researcher of the Year.”
Dr Krill-Jackson on the Practice-Changing Effect of T-DXd in HER2+ Breast Cancer
October 12th 2023Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.